

# Drug Policy

<b>Policy:</b>	<b>Omega-3 Fatty Acid Products</b>	<b>Annual Review Date:</b>
		<b>04/20/2023</b>
	<b>Icosapent Ethyl (generic of Vascepa)</b>	<b>Last Revised Date:</b>
	<b>Lovaza (omega-3 acid ethyl esters)</b>	<b>04/20/2023</b>
	<b>Omega-3-acid Ethyl Esters (generic of Lovaza)</b>	
	<b>Triklo (omega-3-acid ethyl esters)</b>	
	<b>Vascepa (icosapent ethyl)</b>	

## OVERVIEW

Lovaza and Vascepa are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( $\geq 500$  mg/dL) hypertriglyceridemia. Vascepa is also indicated for risk reduction of myocardial infarction (MI), stroke, coronary revascularization, and unstable angina requiring hospitalization in patients with elevated triglyceride levels  $\geq 150$  mg/dL. Lovaza is a combination of ethyl esters of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The daily dose of Lovaza is 4 g/day taken as a single 4-gram dose (four capsules) or as two 2-gram doses (two capsules given twice daily [BID]). Each 1-gram capsule of Lovaza contains at least 900 mg of ethyl esters of omega-3 fatty acids sourced from fish oils (approximately 465 mg of EPA and 375 mg of DHA). Vascepa is an ethyl ester of the omega-3 fatty acid EPA. The daily dose of Vascepa is 4 g/day taken as four 0.5 gram capsules BID with food or as two 1-gram capsules BID with food. The safety and effectiveness in pediatric patients have not been established for either of these agents. The most common adverse events (AEs) of Lovaza include dyspepsia, eructation, taste perversion, and arthralgia, while Vascepa is associated with musculoskeletal pain, peripheral edema, constipation, gout, atrial fibrillation, arthralgia and oropharyngeal pain. Both agents have it noted in their prescribing information that the effects on the risk for pancreatitis have not been determined. Of note Epanova (omega-3-carboxylic acid capsules) and Omtryg™ (omega-3-acid ethyl esters A capsules) are two other omega-3 fatty acid products that were approved by the FDA with similar indications but have not been marketed yet. They are not discussed further in this document.

## POLICY STATEMENT

This policy involves the use of Omega-3 Fatty Acid products. Prior authorization is recommended for pharmacy benefit coverage of Lovaza and Vascepa. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Omega-3 Fatty Acid products is recommended in those who meet the following criteria:

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>.

# Drug Policy

## 1. Severe Hypertriglyceridemia with Triglyceride (TG) Levels 500 mg/dL or higher (all products).

**Criteria.** Patient must meet the following criteria (A, B, C, and D):

- A. The patient is 18 years of age or older; AND
- B. The patient has a fasting baseline (pre-treatment) triglyceride (TG) level of  $\geq 500$  mg/dL; AND
- C. The patient has tried, or is currently receiving ONE of the following products for at least 90 days AND has not achieved adequate efficacy according to the prescribing physician (a, b, or c):
  - a. A fibrate (e.g. gemfibrozil, fenofibrate, fenofibric acid); OR
  - b. A statin (e.g. atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin); OR
  - c. An over-the-counter (OTC) omega-3 fatty acid product (e.g. fish oil supplements) at maximum recommended dosage; AND
- D. The patient has been on and will continue an appropriate lipid-lowering diet and exercise regimen; AND
- E. If brand Lovaza is requested, the patient has failed a trial of generic omega-3 acid ethyl esters for a minimum of 90 days [documentation required]

## 2. Risk Reduction of Myocardial Infarction (MI), Stroke, Coronary Revascularization, and Unstable Angina Requiring Hospitalization in Patients with Elevated Triglyceride Levels $\geq 150$ mg/dL (Vascepa and generic icosapent only)

**Criteria.** Patient must meet the following criteria (A, B, C, D, and E):

- A. The patient is 18 years of age or older; AND
- B. Vascepa will be used as an adjunct to maximally tolerated statin therapy [documentation required]; AND
- C. Vascepa is being used to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and unstable angina requiring hospitalization in patients; AND
- D. The patient has a fasting baseline (pre-treatment) triglyceride (TG) level of  $\geq 150$  mg/dL; AND
- E. The patient meets one of the following criteria (a or b):
  - a. The patient has established cardiovascular disease as defined as one of the following [documentation required] (i, ii, iii, iv, v, vi, vii, viii, or ix):
    - i. Multivessel coronary artery disease (CAD); OR
    - ii. Prior MI; OR
    - iii. Hospitalization for high-risk acute coronary syndrome (ACS); OR
    - iv. Prior ischemic stroke; OR
    - v. Symptomatic carotid artery disease with  $\geq 50\%$  carotid arterial stenosis; OR
    - vi. Asymptomatic carotid artery disease with  $\geq 70\%$  carotid arterial stenosis; OR
    - vii. History of carotid revascularization; OR
    - viii. Ankle brachial index (ABI)  $< 0.9$  with symptoms of intermittent claudication; OR
    - ix. History of aortoiliac or peripheral arterial intervention; OR
  - b. The patient has diabetes mellitus with **two** or more additional risk factors for cardiovascular disease defined below (i, ii, iii, iv, v, vi, vii, viii, or ix):
    - i. The patient is a man  $\geq 55$  years of age OR a woman  $\geq 65$  years of age; OR
    - ii. The patient is a cigarette smoker or has stopped smoking within the past 3 months; OR

# Drug Policy

- iii. The patient has hypertension (HTN) defined as BP  $\geq$ 140 mm Hg systolic OR  $\geq$ 90 mm Hg diastolic OR the patient is on antihypertensive medication; OR
- iv. The patient is a man with an HDL-C  $\leq$  40 mg/dL or a woman with an HDL-C  $\leq$  50 mg/dL; OR
- v. The patient has a high-sensitivity C-reactive protein (hsCRP) level  $>$  3.00 mg/L (0.3 mg/dL); OR
- vi. The patient has renal dysfunction defined as a creatinine clearance (CrCl) between 30 and 60 mL/min; OR
- vii. The patient has retinopathy; OR
- viii. The patient has microalbuminuria OR macroalbuminuria; OR
- ix. The patient has an ABI  $<$  0.9 without symptoms of intermittent claudication

## Initial Approval/ Extended Approval.

- A) *Initial Approval:* 1 year
- B) *Extended Approval:* 1 year

---

## CONDITIONS NOT RECOMMENDED FOR APPROVAL

Omega-3 Fatty Acid products have not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company.

Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

## REFERENCES

1. Lovaza® capsules [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2015.
2. Vascepa® capsules [prescribing information]. Bedminster, NJ: Amarin; February 2017.
3. Epanova® capsules [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; May 2014.
4. Omtryg™ [prescribing information]. Arlington, CA: Trygg Pharma; April 2014.
5. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2011;123:2292-2333. Available at <http://circ.ahajournals.org/content/123/20/2292.full.pdf+html>. Accessed on April 11, 2017.
6. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis. *Endocrin Pract*. 2017;2(Suppl 2):1-87.

---

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>.

# Drug Policy

7. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2012;97(9):2969-2989.
8. Davidson MH, Stein EA, Bays HE, et al, for the COMBination of prescription Omega-3 with Simvastatin (COMBOS) investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. *Clin Ther.* 2007;29(7):1354-1367.
9. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR 101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR) study. *Am J Cardiol.* 2012;110(7):984-992.
10. Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. *Lipids Health Dis.* 2016;15(1):118.
11. Omega-3-acid ethyl esters. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 20 May 2021. Accessed 16 February 2022.
12. Icosapent ethyl. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 15 December 2021. Accessed on 16 February 2022.